Making the undruggable druggable
Unlocking challenging drug targets for the development of next-generation therapeutics
Selected Collaborations
It all starts with the drug target.
The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.
Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.
Pushing drug development forward together
We work with top-tier pharma and biotech partners to unlock drug targets for drug development programs.
Pipeline
We are driving forward drug development in our partnered as well as internal pipelines.
News
Salipro Biotech at Asia Bio 2025
2025-08-26
Salipro Biotech is heading to Singapore!
We’re excited to join the Swedish Life Science Delegation at Asia Bio 2025, taking place 9-10 September, to strengthen ties with Singapore’s leading vibrant pharma and biotech ecosystem.
As part of the program organized by Business Sweden, Swecare, and SwedenBIO, we look forward to engaging with key stakeholders, exploring strategic partnerships, and showcasing the Salipro® platform to unlock challenging membrane protein drug targets.
Lorena Galán, BD Manager, will be at the conference and available for partnering meetings throughout the event.
We look forward to connecting face-to-face with biotech and pharma leaders in Asia. Let’s meet and discuss how Salipro® can accelerate your drug discovery goals addressing tough targets!
Partnering system is now open - book your meeting with us here: https://partneringone.informaconnect.com/event/797/profile/user/89/company/62
From Collaboration to Publication: Salipro® Enables GPCR Antibody Discovery
2025-08-21
We're glad that our partnership with Bio-Rad Laboratories is featured in their new publication in mAbs: “Pioneer: A Synthetic Human Antibody Phage Display Library for Rapid Therapeutic Lead Generation.”
Targeting GPCRs like CXCR4 is a major challenge in antibody discovery. Using our Salipro® platform, we stabilized CXCR4 in its native form, enabling Bio-Rad’s Pioneer™ library to generate a diverse panel of high-affinity, functional antibodies.
This synergistic approach was a clear success, leading to the direct identification of multiple high-affinity, functionally active anti-CXCR4 antibodies with excellent developability. The Salipro® platform unlocks access to challenging membrane protein targets, and Bio-Rad's Pioneer™ platform rapidly turns them into high-quality therapeutic candidates. Together, these platforms enable the pursuit of entirely new therapeutic avenues.
Congratulations to all teams and collaborators at Bio-Rad on this achievement and publication! We look forward to seeing how these technologies will continue to accelerate the development of new medicines for patients in need.
Read the full paper here:
M. Putyrski, M., et al., Pioneer: a synthetic human antibody phage display library for rapid therapeutic lead generation. mAbs, 17(1) (2025).
New study with Salipro® - Reprogramming Cancer Cells to Fight Themselves
2025-07-08
We are excited to share a new study published in Cell Discovery that opens new avenues in cancer treatment by reprogramming cancer metabolism to enhance immune responses and fight tumors.
Targeting complex membrane protein assemblies - like the Basigin-MCT transporter - has long been a major challenge in oncology. Understanding how to modulate their function is critical for creating effective new therapies. The study introduces a novel antibody that reprograms the basigin protein, transforming it from a tumor enabler into a suppressor of the cancer’s metabolic fuel supply.
With the Salipro® platform, the researchers achieved high-resolution cryo-EM and molecular dynamics simulations, revealing the precise mechanism by which the antibody modulates MCT1 and MCT4 transporters.
This structural insight provides a detailed map of the antibody-protein interaction, paving the way for more precise medicines with potentially fewer side effects.
Congratulations to the teams for their contribution to the fields of cancer biology and structural immunology!
Find the full study:
H. Zhang, et al., A basigin antibody modulates MCTs to impact tumor metabolism and immunity. Cell Discovery, (2025).